Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.8
Journals
Pharmaceuticals
Special Issues
Application of Nanotechnology in Drug Delivery
share announcement

Application of Nanotechnology in Drug Delivery

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 31 May 2026 | Viewed by 983

Special Issue Editors

Dr. Camila Batista Da Silva

E-Mail Website
Guest Editor
Department of Biosciences, Piracicaba Dental School, Universidade Estadual de Campinas, Sao Paulo, Brazil
Interests: dentistry; anesthesia; local anesthesia; anxiety; pain; drug delivery
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Michelle Franz-Montan

E-Mail Website
Guest Editor
Department of Biosciences, Piracicaba Dental School, University of Campinas (UNICAMP), Piracicaba, São Paulo 13083-970, Brazil
Interests: topical anesthesia; oral cavity; oral mucosa; dental anesthesia; drug delivery; mucoadhesive system; dentistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Issue aims to bring together groundbreaking research and innovative approaches that highlight the transformative potential of nanotechnology in the pharmaceutical sciences. The field of drug delivery has advanced significantly with the advent of nanomaterials, offering enhanced precision, targeted therapy, and improved bioavailability, ultimately leading to more effective and safer treatments.

The integration of nanotechnology into drug delivery has provided solutions to longstanding challenges in medicine, such as controlling drug release, reducing side effects, and improving therapeutic outcomes. From liposomes and polymeric nanoparticles to cutting-edge biomimetic nanocarriers, these technologies have the potential to revolutionize personalized medicine and pave the way for more efficient treatments across various medical fields. This Special Issue aims to showcase research that contributes to the development and optimization of nanotechnology-based delivery systems.

We appreciate the valuable contributions from researchers worldwide and hope that this collection serves as a platform for knowledge exchange, inspiring further advancements in nanomedicine. By fostering collaboration and innovation, we aim to drive forward the next generation of drug delivery solutions. We look forward to an engaging and insightful discussion within this Special Issue Application of Nanotechnology in Drug Delivery.

Dr. Camila Batista Da Silva
Prof. Dr. Michelle Franz-Montan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug discovery
  • drug combinations
  • nanotechnology
  • drug liberation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 1142 KB  
Article
Rifampicin/Quercetin Nanoemulsions: Co-Encapsulation and In Vitro Biological Assessment Toward Tuberculosis Therapy
by Frank do Carmo Guedes Júnior, Gabriela Hädrich, Camila de Oliveira Vian, Gustavo Richter Vaz, Virginia Campello Yurgel, Daniela Pastorim Vaiss, Gabriela Alves Felício da Costa, Marcelle Oliveira Garcia, Wanessa Maria dos Santos, Beatriz Sodré Matos, Lara Cristina dos Santos Teodoro, João Victor Villa Real, David Nascimento da Silva Teixeira, Alexandre de Paula Rogério, Sergiane Caldas Barbosa, Ednei Gilberto Primel, Pedro Eduardo Almeida da Silva, Daniela Fernandes Ramos and Cristiana Lima Dora
Pharmaceuticals 2025, 18(12), 1829; https://doi.org/10.3390/ph18121829 - 1 Dec 2025
Viewed by 262
Abstract
Background: Tuberculosis (TB) remains a leading cause of global mortality, with 1.25 million deaths reported in 2023. Extended treatment duration contributes to poor patient adherence and treatment failure. Innovative drug delivery platforms are needed to improve therapeutic outcomes. Objective: This study [...] Read more.
Background: Tuberculosis (TB) remains a leading cause of global mortality, with 1.25 million deaths reported in 2023. Extended treatment duration contributes to poor patient adherence and treatment failure. Innovative drug delivery platforms are needed to improve therapeutic outcomes. Objective: This study aimed to develop nanoemulsions co-encapsulating quercetin and rifampicin and evaluate their physicochemical properties and in vitro biological activity relevant to TB therapy. Methods: Nanoemulsions (NEs) were prepared via hot solvent diffusion and phase inversion temperature techniques. Physicochemical characterization, stability, anti-inflammatory effects in BEAS-2B cells, and antimycobacterial activity against Mycobacterium tuberculosis H37Rv and resistant strains were assessed in vitro. Results: The quercetin-rifampicin nanoemulsion (QUE-RIF-NE) showed an average size of 24 nm, zeta potential of −27 mV, and drug recovery rates of 77% (quercetin) and 75% (rifampicin). The formulation was stable and non-cytotoxic at 10−8 M, reducing IFN-γ production by half and reactive oxygen species production by almost 75% in BEAS-2B cells. It also exhibited antimycobacterial activity against both susceptible and resistant M. tuberculosis strains (MIC ≤ 0.015 µg/mL). Conclusions: QUE-RIF-NE exhibits promising physicochemical stability and dual anti-inflammatory and antimicrobial activity in vitro, demonstrating potential for optimized pulmonary or systemic TB therapy that integrates both anti-inflammatory and antimicrobial effects. Full article
(This article belongs to the Special Issue Application of Nanotechnology in Drug Delivery)
►▼ Show Figures

Graphical abstract

12 pages, 3194 KB  
Article
Development of a Drug Delivery System Using a Compound Based on Ethyl Cyanoacrylate and Hancornia speciosa (Gomes) in a Rat Calvaria Model
by Daniel Felipe Fernandes Paiva, Marco Antonio Tridapalli Mafra, Victor Augusto Benedicto dos Santos, Sidney Raimundo Figueroba, Anne Caroline Gercina Carvalho Dantas, Klinger de Souza Amorim, Francisco Haiter Neto, Camila Batista da Silva and Francisco Carlos Groppo
Pharmaceuticals 2025, 18(11), 1695; https://doi.org/10.3390/ph18111695 - 8 Nov 2025
Viewed by 361
Abstract
Background/Objectives: Regenerating critical-sized bone defects is a significant clinical challenge. Autogenous bone grafts are the gold standard but have limitations, including donor site morbidity. As an alternative, this study introduces a novel biocomposite combining an ethyl cyanoacrylate (ECA) polymer with Hancornia speciosa [...] Read more.
Background/Objectives: Regenerating critical-sized bone defects is a significant clinical challenge. Autogenous bone grafts are the gold standard but have limitations, including donor site morbidity. As an alternative, this study introduces a novel biocomposite combining an ethyl cyanoacrylate (ECA) polymer with Hancornia speciosa (Hs) latex. The ECA acts as a scaffold and delivery vehicle for the latex, which contains phytochemicals with known angiogenic properties. Methods: We created 5 mm critical-sized calvarial defects in 36 Wistar rats, which were divided into four experimental groups. Bone regeneration was evaluated at 30, 60, and 90 days using micro-computed tomography (micro-CT) for morphometric analysis and hematoxylin and eosin staining for histology. Results: The composite-treated group (Hs+ECA) showed significantly higher bone volume (57.2; IQR: 56.7–61.2) than the control (53.9; IQR: 49.4–56.4) and ECA-only (48.4; IQR: 47.2–59.9) groups at 90 days (p < 0.05). By day 60, the bone volume in the Hs+ECA group was statistically similar (p > 0.05) to that of the autogenous bone group. Histological analysis revealed an organized repair process with neoangiogenesis observed only in the Hs+ECA group, confirming the material’s strong bioactivity. Conclusions: The Hs+ECA composite is a promising biomaterial that acts as an effective delivery system for the bioactive components of the latex. The induced angiogenesis was critical to its regenerative success. This cost-effective material warrants further investigation for clinical applications in regenerative dentistry. Full article
(This article belongs to the Special Issue Application of Nanotechnology in Drug Delivery)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop